A Closer Look Prostate Cancer Test
Date: April 20, 2010
While the PSA (prostate specific antigen) test has led to earlier detection
of prostate cancers, the test also has a high rate of false positive results.
DR. WILLIAM NELSON and team discovered the most common
genome alteration in prostate cancer. They developed a biomarker test
that can be used in conjunction with PSA to detect precancerous
changes and prostate cancer.
Johnson & Johnson has licensed the test making mass distribution
and broad-based use possible.